论文部分内容阅读
众所周知,血小板在动脉血栓形成中起到了关键的作用,抗血小板治疗已成为急性冠脉综合征患者预防和治疗动脉血栓的基石。氯吡格雷作为一种新型抗血小板药物,对心血管病的重要辅助治疗作用已得到证实。但研究发现,大约有11%～44%患者对氯吡咯雷表现为低反应甚至无反应,定义为氯吡格雷抵抗。而导致此种抵抗现象的可能原因是氯吡格雷给药剂量不足,个体的基因多态性和药物之间的相互作用等。其主要对策有提高氯吡格雷的给药剂量,联用其它抗血小板药物,减少药物的不良相互作用和采用新型药物等。
It is well-known that platelets play a key role in arterial thrombosis. Antiplatelet therapy has become the cornerstone of the prevention and treatment of arterial thrombosis in patients with acute coronary syndromes. As a new antiplatelet agent, clopidogrel has been shown to be an important adjuvant therapy for cardiovascular disease. But the study found that about 11% to 44% of patients showed low response to clopidogrel or even no response, defined as clopidogrel resistance. The possible causes of this resistance phenomenon are lack of dose of clopidogrel, individual genetic polymorphisms and the interaction between drugs. The main countermeasure is to increase the dosage of clopidogrel, combined with other anti-platelet drugs, reduce the adverse drug interactions and the use of new drugs.